<DOC>
	<DOCNO>NCT00678743</DOCNO>
	<brief_summary>The primary objective trial ass continue efficacy Omacor co-administered simvastatin lower non-high-density lipoprotein cholesterol ( non-HCL-C ) level .</brief_summary>
	<brief_title>An Open-Label Extension Assess Continued Efficacy Omacor Plus Simvastatin</brief_title>
	<detailed_description>The present trial open-label , uncontrolled extension previous trial ( PRV-06009 ) utilize randomize , double-blind , two-period crossover design eight clinic vists . The current trial consist nine clinic visit 104 week . There two treatment period study : - Phase I : All subject receive simvastatin 80 md/d plus Omacor 4 g/d first six week trial . - Phase II : All subject receive simvastatin ( dose determine discretion Investigator ) plus Omacor 4 g/d remainder treatment period .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Must meet relevant inclusion/exclusion criterion prior throughout previous doubleblind study ( PRV06009 ) Must complete previous doubleblind study week 12 . Provide write informed consent authorization protect health information Study drug compliance le 50 % PRV06009 Any ongoing serious adverse event PRV06009</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>cholesterol</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>omega 3</keyword>
</DOC>